COMMUNIQUÉS West-GlobeNewswire

Sonablate Announces Landmark Global Strategic Alliance with Eleven Ventures to Advance AI-Powered Precision Medicine
06/08/2026
Agreement establishes long-term commitment to support global expansion of Sonablate’s therapeutic ultrasound technology and facilitate up to $200 million in strategic capital formation JEDDAH, Saudi Arabia and CHARLOTTE [...]
Philips expands open patient monitoring ecosystem to help health systems keep sight of patients beyond the bedside
06/08/2026
August 6, 2026 New collaborations expand wearable and out-of-hospital monitoring capabilities, helping support continuous patient visibility from admission through recovery at home Amsterdam, Netherlands. – Royal [...]
Alpha Pro Tech, Ltd. Announces Second Quarter 2026 Financial Results
06/08/2026
Second Quarter Net Sales Increased by 12% to $18.7 Million from $16.7 Million in the Second Quarter of 2025; Second Quarter Net Income Increased by 47% to $1.8 Million from $1.2 Million in the Prior Year Period Net [...]
Kyntra Bio to Report Second Quarter 2026 Financial Results
06/08/2026
SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce second quarter 2026 financial results on Thursday, August 13 after market close. Kyntra Bio will also conduct a conference [...]
Sharecare launches AskMD nationwide to turn any health question into a personalized plan
06/08/2026
ATLANTA, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Sharecare today announced that AskMD, its AI-powered health navigation experience grounded in each individual’s medical history, health plan, and location, is now available [...]
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
06/08/2026
Collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability and enterprise adoption SARASOTA, FLA., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma ( [...]
Milestone Scientific Schedules Second Quarter 2026 Financial Results Conference Call
06/08/2026
ROSELAND, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that [...]
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
06/08/2026
ISELIN, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) [...]
SeaStar Medical to Report Second Quarter Financial Results on August 12, 2026
06/08/2026
DENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure [...]
Actimed Therapeutics Reacquires Global Rights to S-oxprenolol, Broadening Pipeline Opportunity
06/08/2026
London, UK – 6 th August 2026. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]
IBA Notice of Half Year 2026 Results and Conference Call
06/08/2026
HY26 results webcast to take place on Thursday, 27 August 2026 at 3 p.m. CEST Louvain-la-Neuve, Belgium, 6 August 2026, 7 a.m. - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator [...]
IBA : Publication des résultats du premier semestre 2026 et conférence web
06/08/2026
La conférence sur les résultats du premier semestre 2026 aura lieu le jeudi 27 août 2026 à 15h00, heure de Bruxelles Louvain-la-Neuve, Belgique, le 06 août 2026, 7h00 - IBA (Ion Beam Applications S.A le leader mondial [...]
Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update
06/08/2026
Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update Strategic partnering remains a key priority, with multiple strategic discussions progressing, including advanced term sheet [...]
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
06/08/2026
SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other [...]
ARCPOINT ANNOUNCES FAILURE-TO-FILE CEASE TRADE ORDER
06/08/2026
GREENVILLE, South Carolina, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint ”) announces that the British Columbia Securities Commission (the “ BCSC ”), as the Company’s [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals
06/08/2026
NANJING, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its Phase II clinical study evaluating Opamtistomig (LBL-024 [...]
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
06/08/2026
IRVINE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Thursday, August 6, 2026 to report its [...]
CellFiber and Tidewave Bio Enter Collaboration to Evaluate Scalable 3D Manufacturing for Next-Generation Solid Tumor Immunotherapy
06/08/2026
Partnership pairs CellFiber’s proprietary hollow-fiber encapsulation platform with Tidewave Bio’s universal, off-the-shelf cell immunotherapy program in a proof-of-concept process evaluation TOKYO and LOS ANGELES, Aug. [...]
UPDATE - LifeMD Reports Second Quarter 2026 Results
06/08/2026
UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of [...]

Pages